Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Suresh Anne

Allergy & Immunology Flint, MI Medical Doctor

NPI 1336101443 CMS profile 196810

5155 Norko Dr, Flint, MI 48507

Open in the dashboard

General payments

$14,545

698 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,118,520 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Suresh Anne of Flint, MI is reported in the CMS Open Payments database as having received $14,545 across 698 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,118,520 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 80th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,096 141
2024 General $2,552 107
2023 General $2,386 105
2022 General $2,623 126
2021 General $1,117 64
2020 General $1,100 56
2019 General $1,672 99

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Suresh Anne
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Suresh Anne were reported at $3,096. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Suresh Anne Allergy & Immunology median Middle half National median
2019 $1,672 $594 $163–$1,512 $163
2020 $1,100 $426 $106–$1,233 $114
2021 $1,117 $638 $157–$1,708 $132
2022 $2,623 $790 $205–$1,961 $149
2023 $2,386 $852 $220–$2,147 $160
2024 $2,552 $865 $203–$2,267 $164
2025 $3,096 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,658 107 payments
  2. GlaxoSmithKline, LLC. $1,913 152 payments
  3. CSL Behring $1,470 65 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $1,317 51 payments
  5. Regeneron Healthcare Solutions, Inc. $1,028 43 payments
  6. Genzyme Corporation $933 36 payments
  7. Amgen Inc. $746 32 payments
  8. Pfizer Inc. $720 36 payments
  9. BioCryst US Sales Co., LLC $444 18 payments
  10. Pharming Healthcare, Inc. $281 11 payments
  11. Other $3,033 147 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,198 686 payments
  2. Education $306 10 payments
  3. Consulting Fee $41 2 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $1,522 55 payments
  2. FASENRA $938 51 payments
  3. DUPIXENT Inflammation And Immunology $931 39 payments
  4. Haegarda $840 35 payments
  5. CUVITRU $829 28 payments
  6. NUCALA $763 71 payments
  7. TEZSPIRE $666 28 payments
  8. PANZYGA $664 29 payments
  9. AIRSUPRA $624 12 payments
  10. CUTAQUIG $609 26 payments
  11. Other $7,737 395 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 48 drugs

Part D claims

4,422

Median for Allergy/ Immunology: 449

Drug cost

$2,073,251

Median for Allergy/ Immunology: $169,700

Branded share of claims

25.7%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 145 $528,103
Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 Brand 55 $483,049
Gammaplex Immun Glob G(Igg)/Gly/Iga 0-50 Brand 50 $288,015
Xolair Omalizumab Brand 60 $161,779
Dupixent Syringe Dupilumab Brand 29 $113,407
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 122 $96,287
Nucala Mepolizumab Brand 24 $82,738
Rinvoq Upadacitinib Brand 12 $74,026
Tiotropium Bromide Generic 68 $45,073
Spiriva Respimat Tiotropium Bromide Brand 38 $37,434

The 10 drugs with the highest cost, of 48 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$185,486

Of which drugs: $124,925

Medicare patients

299

Average age 69

Services billed

7,143

189 women, 110 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Diabetes 32%
Ischemic heart disease 26%
Depression 23%
Chronic kidney disease 22%
COPD 19%
Heart failure 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 17 17 $1,358

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $172
  • Regeneron Healthcare Solutions, Inc. $121
  • SANOFI-AVENTIS U.S. LLC $90
$383 174 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $285
$285 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $249
$249 — —
CUVITRU
  • Takeda Pharmaceuticals U.S.A., Inc. $241
$241 — —
Haegarda
  • CSL Behring $194
$194 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

698 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record